BrainStorm Cell Therapeutics Inc. Will Host a Conference Call to Update Shareholders on Upcoming Trial and Other Exciting Developments Business Wire NEW YORK & PETACH TIKVAH, Israel -- November 29, 2012 BrainStorm Cell Therapeutics Inc. (OTC:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that its senior management will hold a conference call on Tuesday, December 11, 2012 at 8:00 a.m. EST in Hebrew and at 8:45 a.m. EST in English. Dr. Adrian Harel, Chief Executive Officer, Mr. Chaim Lebovits, President, Ms. Liat Sossover, Chief Financial Officer, and Prof. Eldad Melamed, PhD, Chief Medical Advisor, will update on the upcoming trial and other exciting developments. Callers may participate in the conference call, in Hebrew at 08:00 a.m. EST (03:00 p.m. Israel time), by dialing: USA: 1-888-407-2553 Israel: 1-800-270-345 International: +972-3-918-0610 Callers may participate in the conference call, in English at 08:45 a.m. EST, by dialing: USA: 1-888-668-9141 Israel: 1-800-227-297 International: +972-3-918-0609 Callers are invited to ask relevant questions during the conference call. Questions may also be pre-submitted to firstname.lastname@example.org prior to 7:00 a.m. EST on Thursday, December 6, 2012. A recording of the conference will be available for download Monday, December 17, 2012 from the company’s website. About BrainStorm Cell Therapeutics BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. For more information, visit the company’s website at www.brainstorm-cell.com. Safe Harbor Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may,” “should,” “would,” “could,” “will,” “expect,” “likely,” “believe,” “plan,” “estimate,” “predict,” “potential,” and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Contact: BrainStorm Cell Therapeutics Inc. (OTC: BCLI) Adrian Harel, Ph.D., CEO +972-3-9236384 email@example.com www.brainstorm-cell.com
Tesco to Investigate Overstatement of Profit by About $410M
BrainStorm Cell Therapeutics Inc. Will Host a Conference Call to Update Shareholders on Upcoming Trial and Other Exciting
Press spacebar to pause and continue. Press esc to stop.